Angion Biomedica and Vifor Pharma announced that their Phase III trial on ANG-3777 for renal transplant patients did not meet the study’s primary and secondary endpoints.
https://www.pharmalive.com/wp-content/uploads/2021/10/Angion-and-Vifor-Disappointed-After-Phase-III-Kidney-Transplant-Study-Fails-BioSpace-10-27-21.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-10-27 11:38:142021-10-27 12:42:46Phase III Kidney Transplant Study Fails